The biomanufacturing sector, strategic for healthcare, industry and health sovereignty

Challenges & Priorities

Biological medicines are ushering in a new era of treatment. Monoclonal antibodies, cell and gene therapies, next-generation vaccines: these innovations are already transforming the treatment of many diseases and offering new possibilities to millions of patients. 10 million patients in France affected by cancer, autoimmune or inflammatory diseases.

Behind each of these innovations lies a major challenge:producing them at scale, to high-quality standards and within timeframes that meet patients’ needs. This is the key challenge of biopharmaceutical manufacturing.

This sector brings together the entire biopharmaceutical value chain:

  • academic research
  • biotech companies
  • the pharmaceutical industry
  • CDMOs and technology providers
  • equipment manufacturers
  • training providers
  • the healthcare ecosystem and regions

"Biomanufacturing has become a strategic priority for France. It is no longer solely about scientific innovation: it is now a major industrial challenge.

"Biomanufacturing has become a strategic priority for France. It is no longer solely about scientific innovation: it is now a major industrial challenge.

Our ability to manufacture the biological medicines of tomorrow in France is critical to our health sovereignty, our competitiveness and patients’ access to treatments. To meet this challenge, the sector must continue to work together to strengthen its foundations, accelerate, invest and innovate. This is the ambition that France BioLead champions alongside stakeholders from across the ecosystem.”

By bringing together stakeholders from across this value chain, France BioLead creates the conditions needed to accelerate the transition from scientific innovation to industrial production.

Why is biomanufacturing strategic?

Global competition is intensifying. The United States, China and South Korea are investing heavily to attract businesses and expand their industrial capabilities.

Mastering biomanufacturing capabilities is now critical to:

  • give patients faster access to therapeutic innovations
  • translate scientific discoveries into biological medicines more quickly
  • attract international investment
  • create highly skilled jobs
  • strengthen French and European industrial competitiveness
  • secure medicine supplies during health crises
  • build a more resilient industry in the face of geopolitical and health challenges
France’s Strengths

France’s Strengths

France has many strengths that can position it among the world leaders in biomanufacturing:

  • internationally recognised academic research
  • leading pharmaceutical manufacturers
  • a dynamic ecosystem of innovative biotech companies
  • high-performing technology platforms
  • high-quality hospital infrastructure
  • recognised scientific and industrial expertise
  • a training network covering all occupations across the sector

These strengths provide a solid foundation for building a competitive and sovereign sector.

The Sector's Key Challenges

Accelerating Innovation

Accelerating Innovation 

France has a world-class scientific research base. The challenge now is to accelerate the transition from discovery to clinical trials and then to industrial production, enabling more biological medicines to be developed and manufactured in France. 

Strengthening Collaboration between Public Research and Industry

Strengthening Collaboration between Public Research and Industry

France has one of the world’s leading academic research bases. To translate this scientific excellence into therapeutic innovations and industrial success, collaboration between public research laboratories, hospitals, biotech companies, manufacturers and technology platforms must be strengthened further.

Fostering collaborative projects, accelerating technology transfer, sharing expertise and better aligning industry needs with research capabilities are essential to shorten the time from scientific discovery to patients gaining access to the biological medicines of tomorrow.

Developing Biomanufacturing Technologies

Developing Biomanufacturing Technologies

The biological medicines of tomorrow require increasingly high-performing, automated and sustainable manufacturing processes. Investment in biomanufacturing technologies, equipment, digital tools, sensors, AI and digital twins is essential to improve quality, accelerate process development, enhance industrial performance and support the scaling up of production.

Strengthening Competitiveness

Strengthening Competitiveness 

In an increasingly competitive international environment, France must provide a favourable environment for industrial investment, streamline regulatory pathways and strengthen the appeal of its ecosystem to attract the most innovative projects.

Manufacturing in France and Europe

Manufacturing in France and Europe

Having high-performing manufacturing capabilities has become essential to secure the supply of biological medicines, support the scaling up of production and reduce dependence on manufacturing outside Europe.

Developing the Skills of Tomorrow

Developing the Skills of Tomorrow

The growth of biomanufacturing is creating new roles and new skills requirements. Developing, attracting and retaining talent is essential to support the sector’s growth.

> Futurs talents
Building a High-Performing Sector

Building a High-Performing Sector

Successful biomanufacturing depends on close collaboration between research, industry, technology providers, regions and public authorities. Strengthening this collaboration helps accelerate innovation, pool expertise and generate greater benefits across the entire value chain.

A Shared Ambition

Making France one of Europe’s leaders in biomanufacturing cannot be achieved by any one stakeholder alone.

Achieving this ambition requires the entire ecosystem to work together: public research, biotech companies, manufacturers, technology platforms, solution providers, training providers, regions and public authorities.

This is France BioLead’s mission: to bring this community together, support its development and make biomanufacturing a major driver of competitiveness, national sovereignty and innovation for the benefit of patients.

component bloc not found